Intraperitoneal high-dose cisplatin and etoposide in the first-line treatment of advanced ovarian carcinoma

Intraperitoneal cisplatin and etoposide(PE-IP) therapy was performed to 22 advanced ovarian carcinoma patients with bulky residual disease including 15 with stage III and 7 with stage IV. Cisplatin 200 mg/m(2) and etoposide 350 mg/m(2) were given in 2 L saline I.P. via a reservor (Port-A-Cath). The treatment was repeated every 21 days for 6 courses. Complete clinical response was observed in 3(18%) of 17 patients with clinically evaluable disease and partial response was in 9(53%). Fourteen of 17 patients underwent a second operation and complete pathological remission was found in 1 case. Eight patients are alive and continuously free of disease for 8-46 months. Four are alive with recurrent disease for 9-17 months.